Menopause hormones as a path to healthy aging

For decades, hormone therapy at menopause was controversial, partly due to large trials in 2002 that suggested an elevated breast cancer risk. The picture has since become more nuanced. The study, published in Science, argues that the timing of treatment is critical: women who begin hormone therapy shortly after menopause onset appear to have lower risks of cardiovascular disease and possibly cognitive decline, compared to those who start later or not at all.

The timing window shapes outcomes

This is referred to as the timing hypothesis. The idea is that oestrogen is protective for blood vessels and brain cells, but only when administered while those tissues are still in good condition. Starting too late may reduce or even reverse the protective effects. This frames menopause as a critical juncture in women’s aging biology, not merely a reproductive transition.

The review also examines the postmenopausal ovary, which continues to produce androgens (male sex hormones) after menopause. These appear to play a role in bone health, cognition, and mood, even beyond the fertile years. The authors call for more research into this underappreciated function of the ovary.

Women remain underrepresented in research

A recurring theme in this Science special issue is that women have historically been underrepresented in clinical trials. Much of what is known about cardiovascular health, drug responses, and aging is based on data from men. That skews both diagnosis and treatment. More sex-specific research is needed, particularly in the context of longevity, where women’s biological aging after menopause follows a distinct trajectory.

Read the original article